X

Trial Profile

A Double-Blind, Randomized, Multicenter Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 28 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pregabalin (Primary)
Indications Partial epilepsies
Focus Registrational; Therapeutic Use
Sponsors Pfizer

Most Recent Events

04 Dec 2012 Results presented at the 66th Annual Meeting of the American Epilepsy Society.
22 Feb 2012 Status of the extension trial is completed (EudraCT2009-016850-42).
25 Jan 2012 Actual patient number changed from 73 to 75 as reported by ClinicalTrials.gov (Extension trial: NCT00596466).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com